KM Research Hub
← 返回论文库
已完成 入排:排除 图源:可得 入排置信度 0.98

[Phase Ⅲ, multicenter, randomized, double-blinded, positive-controlled trial on the efficacy and safety of maribavir compared with valganciclovir in the treatment of post-transplant cytomegalovirus infection: Subgroup analysis of AURORA Trial in the Chinese population].

L Xuan, H Huang, L P Xu, Y W Fu, F Chen, Y Wang, S Q Wang, L Dong, J Y Wu, D P Wu

Zhonghua Xue Ye Xue Za Zhi 46(12) 1121-1128

PMID41486656
PMCIDPMC12791048
DOI10.3760/cma.j.cn121090-20250626-00300
发表日期2026-01-05
入排依据:未发现恶性肿瘤人群证据。
摘要

摘要

Objective: This study aimed to compare the efficacy and safety of maribavir and valganciclovir in the treatment of asymptomatic cytomegalovirus (CMV) infection in hematopoietic stem cell transplant (HSCT) recipients. Methods: In this phase 3, multicenter, randomized, double-blind, positive-controlled study, subjects with first episode of asymptomatic CMV infection post-HSCT were randomly assigned in a 1∶1 ratio to receive maribavir (400 mg, twice daily) or valganciclovir (dose-adjusted for renal clearance) for 8 weeks with a follow-up period spanned from 8 to week 20. The primary efficacy endpoint includes confirmed CMV viremia clearance at 8 weeks. Safety assessment included treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs) . Results: The Chinese population subgroup included 18 subjects, comprising 9 subjects each in the maribavir and valganciclovir arms. At 8 weeks, 77.8% of the subjects in both arms achieved confirmed CMV viremia clearance, with an unadjusted difference (maribavir vs valganciclovir) of 0.0% (95% CI: -38.4% to 38.4% ). The proportions of responders who achieved CMV viremia clearance at 8 weeks and maintained it until 16 weeks were 44.4% and 55.6% in the maribavir and valganciclovir arms, respectively, with an unadjusted difference of -11.1% (95% CI: -57.0% to 34.8% ). During the treatment observation period, 100% of subjects in both the maribavir and valganciclovir arms experienced at least one TEAE, causing 11.1% and 33.3% of subjects, respectively, to discontinue the study drug. The incidence of treatment-related SAEs was 0 and 22.2% in the maribavir and valganciclovir arms, respectively. Further, the incidence of neutropenia during the treatment observation period was lower in the maribavir arm than in the valganciclovir arm (22.2% vs 55.6% ) . Conclusion: In the Chinese population, maribavir may be comparable to valganciclovir in clearing CMV viremia to treat HSCT recipients with asymptomatic CMV infection, with acceptable safety and good tolerability, especially being numerically lower than valganciclovir in terms of neutropenia.

KM 提取结果

1 个 Figure · 1 个 KM 面板

进入结果中心
KM Figure1 个面板

图2

图2. 按治疗组列出的研究期间任何时间首次CMV血症清除的累积概率 注 CMV:巨细胞病毒

CMV_

首次CMV血症清除的累积概率

图2 · Panel CMV_

quality_warning 待 EXE 对齐 预期 2 条 已提取 1 条

Panel CMV_ 是同一 图2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示疑似重复轨迹:同一条 KM 曲线可能被重复识别疑似图例或人工水平线:轨迹出现不合理的共同平台曲线缺失:预期 2 条,实际恢复 1 条疑似重复轨迹:同一条 KM 曲线可能被重复识别
查看结果
其他 Figure(1,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

图1图1. AURORA研究的中国亚组分析参与者的入组、随机化和随访情况流程图 注 MBV:马立巴韦;VGCV:缬更昔洛韦;百分比基于随机化参与者的数量
非 KM Figure